2020
Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy
Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy. Health Affairs 2020, 40: 42-52. PMID: 33211536, PMCID: PMC7931245, DOI: 10.1377/hlthaff.2020.02054.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineVaccine efficacyCoronavirus disease 2019 (COVID-19) vaccinesSignificant vaccine hesitancyClinical outcomesClinical trialsVaccination programVaccine hesitancyEpidemic severityVaccineAuthorized vaccinesHealth officialsCumulative infectionsEfficacyVaccine productionDistribution programSeverityOutcomesUrgent needHospitalizationVaccinationInfectionTrialsGlobal efforts
2019
Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study
Bilcke J, Antillón M, Pieters Z, Kuylen E, Abboud L, Neuzil KM, Pollard AJ, Paltiel AD, Pitzer VE. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. The Lancet Infectious Diseases 2019, 19: 728-739. PMID: 31130329, PMCID: PMC6595249, DOI: 10.1016/s1473-3099(18)30804-1.Peer-Reviewed Original ResearchConceptsGross domestic productWTP valuesCountry's gross domestic productOptimal strategyCountry-specific willingnessAverage net benefitHealth economic evaluationsGAVI-eligible countriesTyphoid ViPay valueDomestic productVaccine priceWTP thresholdEconomic evaluationVaccine-related costsNet benefitMiddle-income countriesGavi supportVaccine AllianceRoutine immunisationHospital admissionCountriesTCV introductionDALYsTransmission dynamic model